Initial Feasibility Study of the STENTiT Resorbable Fibrillated Scaffold (RFS). The RFS is Intended to Restore Lumen Patency and Blood Flow to Infrapopliteal Arteries. The RFS is a Fully Electrospun Tubular Device With a Fibrillated Microarchitecture and Designed for Transcatheter Delivery

NCT ID: NCT07006467

Last Updated: 2025-07-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-03
• Study Completion Date: 2027-08-31

Brief Summary

This is the First-In-Human feasibility study of the RFS for below the knee lesions in subjects who experience critical limb ischemia due to the peripheral artery disease. The aim of this study is to investigate if the RFS can be implanted safely and with technical success. Up to 10 subjects will be treated with the RFS at one investigational site. Lesions within the inflow trajectory or side branches may be treated with institutions standard of care prior to treatment of the target lesion. This may include usage of POBA, BMS, DCB, or DES. The target lesion will be predilated with POBA.

Device safety will be assessed throughout the clinical investigation, with primary safety endpoints defined as freedom from Major Adverse Limb Events (MALE) at 30 days follow-up. In addition, MALE at 3-, 6-, 12-, and 24- months follow-up, all adverse events, serious adverse events and all device deficiencies will be captured as secondary endpoints.

Device performance will be based on technical success of the implantation defined as successful delivery and deployment with a residual area stenosis of ≤50% as determined on final perioperative IVUS. Primary patency at day of discharge, 30-days, 3-, 6-, 12-, and 24- months follow up will be captured as secondary performance endpoint and are based on duplex ultrasound for all timepoints and angiography and IVUS at 6-months follow-up.

Conditions

Critical Limb Ischemia (CLI)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RFS arm

Peripheral transluminal angioplasty with the RFS of the below the knee vasculature

Group Type: EXPERIMENTAL

Implantation of RFS

Intervention Type: DEVICE

Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion

Interventions

Implantation of RFS

Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject must provide written informed consent prior to any clinical investigation related procedures.

2. Subject is willing and able to comply with the study procedures, and follow-up schedule.

3. Subject has Critical Limb Ischemia (CLI), Rutherford Becker Clinical Category 4 or 5

4. Subject must be at least 18 years of age.

5. Target lesion located in the tibioperoneal trunk, or 2/3 proximal part of the anterior tibial artery, posterior tibial artery or peroneal artery.

6. Only one target lesion per subject is included, other lesions can be treated per institution's standard of care.

7. At least one infrapopliteal branch without an angiographic significant lesion (≥50% diameter stenosis by angiography).

8. Vessel diameter of 3.0 mm to 3.4 mm. Quantitative imaging (IVUS and angiography) will be used to aid accurate sizing of the vessels.

9. Target lesion length ≤ 18 mm.

10. Target lesion of ≥70% diameter stenosis, per angiographic assessment at the time of the procedure.

11. Target lesion is in an area that may be stented without blocking access to subject main branches, i.e ≥2 mm distanced from any bifurcation.

12. Successful antegrade crossing of the target lesion

Exclusion Criteria

1. Subject is currently participating in another clinical investigation that has not yet reached the primary endpoint.

2. Pregnant or nursing subjects or with planned pregnancy during the clinical investigation follow-up period.

3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.

4. Incapacitated individuals, as defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population.

5. Subject has known hypersensitivity or contraindication to device material and its degradants (poly (L-lactide), poly (glycolic acid), lactic acid, and glycolic acid) that cannot be adequately pre-medicated. Subject has known contrast sensitivity that cannot be adequately pre-medicated.

6. Subject has known allergy hypersensitivity or contraindication to aspirin; or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants such as heparin or bivalirudin, and therefore cannot be adequately treated with study medications.

7. Subject with planned surgery or procedure necessitating discontinuation of antiplatelet medications, within 3 months after index procedure.

8. Subject has life expectancy ≤ 1 year.

9. Subject has had a stroke within the previous 3 months with residual Rankin score of ≥2.

10. Subject has renal insufficiency as defined as an estimated GFR < 30ml/min per 1.73m2

11. Subject has platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC < 3,000 cells/mm3, or hemoglobin < 9.0 g/dl.

12. Subject has known serious immunosuppressive disease (e.g. human immunodeficiency virus), or has severe autoimmune disease, that requires chronic immunosuppressive therapy (e.g. systemic lupus erythematosus, etc.), or subject is receiving immunosuppression therapy for other conditions. Subjects treated for HIV (Human Immunodeficiency Virus) and who have undetectable viral load, such that their immune system is not considered compromised, are eligible.

13. Subject has Body Mass Index (BMI) < 18.

14. Subject has a known coagulation disorder with increased risk of arterial thrombosis. Subject with deep vein thrombosis and disorders that increase the risk of deep vein thrombosis can be included in the study.

15. Subject who requires thrombolysis as a primary treatment modality or requires other treatment for acute limb ischemia of the target limb.

16. Subject has previously had or requires surgical revascularization involving any vessel of the ipsilateral extremity.

17. Subject has signs or symptoms of advanced limb infection or septicemia (fever > 38.5 degrees Celsius, WBC > 15,000 cells/microliter, hypotension) at the time of assessment.

18. Subject with extensive tissue loss salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputation.

19. Subject has tandem lesions at the target lesion site (plaque free zone < 2 cm)

20. Pre-dilatation of the target lesion at the time of study intervention did not reach <50% residual diameter stenosis by angiography.

21. Target lesion that has prior metallic stent implant.

22. Failed PTA of target lesion ≤ 60 days prior to the procedure date.

23. The target vessel has another significant lesion (≥50% diameter stenosis by angiography).

24. Significant stenosis (≥50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.

25. Subject has angiographic evidence of, thrombus, thromboembolism or atheroembolism in the ipsilateral extremity.

26. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting arterial lesions left untreated.

27. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery of the ipsilateral extremity.

28. Target lesion has a high probability that atherectomy will be required at the time of index procedure for treatment of the target vessel.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stentit

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Medical Universiteit Graz

Graz, , Austria

Site Status: RECRUITING

Countries

Austria

Central Contacts

Kim van Noort, PhD

Role: CONTACT

k.vannoort@stentit.com

+3125281513

Facility Contacts

Tanja Pflanzl

Role: primary

tanja.pflanzl@medunigraz.at

+43 316 385 12911

Other Identifiers

CT-10001 VITAL-IT 1

Identifier Type: -

Identifier Source: org_study_id